ProQR Therapeutics (PRQR)
(Real Time Quote from BATS)
$2.00 USD
-0.05 (-2.44%)
Updated Apr 23, 2024 02:52 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Income Statements
Fiscal Year end for ProQR Therapeutics NV falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 7 | 4 | 2 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 7 | 4 | 2 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 42 | 72 | 69 | 48 | 64 |
Income After Depreciation & Amortization | -34 | -68 | -68 | -48 | -64 |
Non-Operating Income | 6 | 5 | -1 | -5 | 1 |
Interest Expense | 2 | 5 | 4 | 0 | 0 |
Pretax Income | -30 | -68 | -73 | -53 | -63 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -30 | -68 | -73 | -53 | -64 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -30 | -69 | -73 | -53 | -64 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -32 | -66 | -65 | -46 | -62 |
Depreciation & Amortization (Cash Flow) | 3 | 3 | 3 | 3 | 2 |
Income After Depreciation & Amortization | -34 | -68 | -68 | -48 | -64 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 81.01 | 71.64 | 64.18 | 50.06 | 41.04 |
Diluted EPS Before Non-Recurring Items | -0.38 | -0.96 | -1.14 | -1.06 | -1.55 |
Diluted Net EPS (GAAP) | -0.38 | -0.96 | -1.14 | -1.06 | -1.55 |
Fiscal Year end for ProQR Therapeutics NV falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 3.54 | 1.49 | 1.31 | 0.70 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 3.54 | 1.49 | 1.31 | 0.70 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 10.29 | 9.54 | 10.92 | 10.78 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -6.75 | -8.05 | -9.61 | -10.08 |
Non-Operating Income | NA | 3.80 | 2.10 | 0.86 | 0.57 |
Interest Expense | NA | 1.58 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -5.91 | -5.94 | -8.74 | -9.50 |
Income Taxes | NA | 0.01 | -0.04 | -0.05 | 0.00 |
Minority Interest | NA | 0.00 | 0.32 | 0.02 | 0.08 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -5.92 | -5.90 | -8.70 | -9.50 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -5.92 | -6.21 | -8.71 | -9.59 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 78.33 | 81.00 | 80.94 | 80.89 |
Diluted EPS Before Non-Recurring Items | NA | -0.08 | -0.08 | -0.11 | -0.12 |
Diluted Net EPS (GAAP) | NA | -0.08 | -0.08 | -0.11 | -0.12 |